Search

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments.

… Tuesday, March 28, 2023 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: MSK Granted Merit Extension from the National Cancer Institute MSK was granted a prestigious two-year merit extension of its Cancer Center Support Grant from the National Cancer

Endometrial cancer is the most common gynecologic malignancy, yet incidence and mortality continue to rise. Advanced and recurrent disease carries a poor prognosis, and there are limited effective treatment options. Gynecologic medical oncologist at Memorial Sloan Kettering Cancer Center, Maria M. Rubinstein, MD, and colleagues conducted a Phase 2 study evaluating the efficacy and safety of PARP inhibitor olaparib plus immunotherapy pembrolizumab in patients with persistent or recurrent CN-H/p53-abnormal endometrial cancer, and concluded that this should be considered a potential treatment option for this population.

… Tuesday, May 5, 2026 Endometrial cancer is the most common gynecologic malignancy, yet incidence and mortality continue to rise. Advanced and recurrent disease carries a poor prognosis, and there are limited effective treatment options. Currently, patients may receive a single-agent therapy, but response

Meet Zhongmin Wang, a fifth-year doctoral student in the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK), who has been awarded the 2021 Chairman’s Prize.

… Wednesday, September 22, 2021 Zhongmin Wang , a fifth-year doctoral student in the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK), has been awarded the 2021 Chairman’s Prize. The competitive award is presented annually and was established by GSK’s Board of Trustees Chair Louis

During the upcoming ASCO Virtual Scientific Program, MSK Chief of Thoracic Oncology Service Charles M. Rudin, MD, PhD, will present a study that found pembrolizumab addition to first-line chemotherapy significantly improved progression-free survival for patients with small cell lung cancer (SCLC).

… Thursday, May 28, 2020 Dr. Charles Rudin Dr. Charles Rudin At the American Society of Clinical Oncology (ASCO) Virtual Scientific Program , Memorial Sloan Kettering (MSK) Chief of Thoracic Oncology Service Charles M. Rudin, MD, PhD , will present a study that found pembrolizumab addition to first-line

Investigators have created the first-ever genetically engineered model of cancer made from human embryonic stem cells in culture.

… Monday, December 1, 2014 Summary Investigators have created the first-ever genetically engineered model of cancer made from human embryonic stem cells in culture. Since the late 1990s, when researchers first reported a technique to isolate and grow human embryonic stem cells, known as ES cells, in culture

Learn about diversity and inclusion at Memorial Sloan Kettering, as people from across MSK share their insights and personal experiences.

… Thursday, October 1, 2020 Memorial Sloan Kettering is committed to having conversations about discrimination, diversity, and inclusion, and creating change. People from across MSK share their personal experiences and insights. Louis Voigt Louis Voigt LOUIS VOIGT Associate Attending Department of Anesthesiology

An international study led by researchers at Memorial Sloan Kettering Cancer Center has identified genetic variants in women with BRCA2 mutations that may increase or decrease their risk of developing breast cancer.

… Thursday, October 28, 2010 An international study led by researchers at Memorial Sloan Kettering Cancer Center has identified genetic variants in women with BRCA2 mutations that may increase or decrease their risk of developing breast cancer . The study was published today online in the open-access journal

Results from the first phase I clinical trial of a new drug were presented at the American Association for Cancer Research’s meeting.

… Monday, April 1, 2019 Summary Early findings from the first phase I clinical trial of a drug called LOXO-195 were presented at the American Association for Cancer Research’s annual meeting in Atlanta. In November 2018, the US Food and Drug Administration approved the targeted therapy larotrectinib (Vitrakvi

Scientists have long known that cancer cells and immune cells have an uncommon hunger for glucose but haven’t understood why. A new study offers an answer.

… Thursday, January 21, 2021 Summary A long-standing mystery is why fast-growing cells, like cancer cells and immune cells, rely on a seemingly inefficient form of metabolizing glucose to power their activities. In a new study, scientists at the Sloan Kettering Institute offer a compelling solution. The

New MSK research provides two examples of computational tools developed at MSK that leverage data about cells’ locations to expand our understanding of cancer.

… Friday, April 26, 2024 New research from Memorial Sloan Kettering Cancer Center (MSK) provides two examples of computational tools developed at MSK that leverage data about cells’ locations to expand our understanding of cancer. One approach describes cellular “neighborhoods” not just in terms of which